Innoforce Pharmaceuticals Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Innoforce Pharmaceuticals Co., Ltd. - overview
Established
2018
Location
Hangzhou, -, China
Primary Industry
Pharmaceuticals
About
Based in Hangzhou, China, Innoforce Pharmaceuticals Co. , Ltd. specializes in pharmaceutical innovations, developing advanced therapies to address unmet medical needs in various therapeutic areas. Innoforce Pharmaceuticals Co.
, Ltd. is focused on creating innovative pharmaceutical solutions. Founded in 2018 in Hangzhou, China, the company has completed a total of 4 deals, with its most recent funding round being a Series A in December 2021 where it raised CNY 375 million. The funding was co-led by South China Venture Capital and Yanyuan Capital, with participation from returning and new investors including Advantech Capital and CICC Capital Management.
The company is led by CEO Yuling Li. Innoforce specializes in innovative solutions across diverse technology sectors, focusing on advanced pharmaceuticals designed to address specific industry challenges. Their core offerings include cell and gene therapies, RNA manufacturing platforms, and other biopharmaceutical products that enhance healthcare delivery. These products are aimed at various therapeutic areas, including oncology and rare diseases, serving clients across global markets, including North America, Europe, and parts of Asia.
Innoforce generates revenue through a structured transaction model that incorporates both B2B and direct-to-consumer sales. Clients typically engage via subscription-based agreements for their pharmaceutical solutions, allowing ongoing access to updates and support. The company leverages partnerships with distributors to expand its reach, offering competitive pricing tailored to various market segments. This diverse revenue model establishes a stable income stream and encourages long-term relationships with healthcare providers.
Innoforce Pharmaceuticals Co. , Ltd. plans to utilize the CNY 375 million raised in its recent Series A funding to advance its GMP biomanufacturing capabilities. This includes establishing a new cell and gene therapy capacity and investing in the development of an RNA manufacturing platform.
The company aims to launch new therapeutic products in the upcoming years while expanding its market presence in North America and Europe by 2023.
Current Investors
South China Venture Capital, Quan Capital, Quan Capital
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.innoforce.com.cn
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.